7,733 reports of this reaction
8.6% of all RANITIDINE HYDROCHLORIDE reports
#1 most reported adverse reaction
BREAST CANCER is the #1 most commonly reported adverse reaction for RANITIDINE HYDROCHLORIDE, manufactured by WinCo Foods, LLC. There are 7,733 FDA adverse event reports linking RANITIDINE HYDROCHLORIDE to BREAST CANCER. This represents approximately 8.6% of all 90,318 adverse event reports for this drug.
RANITIDINE HYDROCHLORIDE has an overall safety score of 95 out of 100. Patients taking RANITIDINE HYDROCHLORIDE who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is moderately reported among RANITIDINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to breast cancer, the following adverse reactions have been reported for RANITIDINE HYDROCHLORIDE:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 7,733 FDA reports for RANITIDINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 8.6% of all adverse event reports for RANITIDINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience breast cancer while taking RANITIDINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.